Paper42015103
SARS-CoV-2 infection and its effects on toxicity and survival in non-metastatic nasopharyngeal carcinoma: a matched cohort study.
Lin X and 8 others. BMC Cancer, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 infection and its effects on toxicity and survival in non-metastatic nasopharyngeal carcinoma: a matched cohort study. Papers, record 42015103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42015103
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SARS-CoV-2 infection and its effects on toxicity and survival in non-metastatic nasopharyngeal carcinoma: a matched cohort study.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nasopharyngeal Carcinoma | Major topic |
| COVID-19 | Major topic |
| Nasopharyngeal Neoplasms | Major topic |
| Chemoradiotherapy | Major topic |
| Humans | |
| Female | |
| Male | |
| Retrospective Studies | |
| Middle Aged | |
| Adult | |
| SARS-CoV-2 | |
| Aged |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AB24010078 | the Key Research and Development Program of Guangxi | PubMed | ||
| 20230127-1 | the Science Research and Technology Development Program of Guilin | PubMed |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30705369 | A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. | Sci Rep | 2019 | https://conductscience.org/library/papers/30705369 | PubMed |
| 2 | 33783535 | Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. | J Radiat Res | 2021 | https://conductscience.org/library/papers/33783535 | PubMed |
| 3 | 24231245 | Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. | Radiother Oncol | 2014 | https://conductscience.org/library/papers/24231245 | PubMed |
| 4 | 26784176 | Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/26784176 | PubMed |
| 5 | 32479790 | Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32479790 | PubMed |
| 6 | 32286310 | Sex-associated molecular differences for cancer immunotherapy. | Nat Commun | 2020 | https://conductscience.org/library/papers/32286310 | PubMed |
| 7 | 32479787 | Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32479787 | PubMed |
| 8 | 32302681 | Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. | Int J Radiat Oncol Biol Phys | 2020 | https://conductscience.org/library/papers/32302681 | PubMed |
| 9 | 39214285 | COVID-19-related liver injury: Mechanisms, diagnosis, management; its impact on pre-existing conditions, cancer and liver transplant: A comprehensive review. | Life Sci | 2024 | https://conductscience.org/library/papers/39214285 | PubMed |
| 10 | 37993681 | Mechanisms and consequences of sex differences in immune responses. | Nat Rev Nephrol | 2024 | https://conductscience.org/library/papers/37993681 | PubMed |
| 11 | 27686945 | Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27686945 | PubMed |
| 12 | 29140166 | Inactivation of a Single Eucaryotic Gene Irradiated in Vitro in Transcriptionally Active Chromatin Form. | Radiat Res | 1986 | https://conductscience.org/library/papers/29140166 | PubMed |
| 13 | 38463154 | Assessing the impact of interventions on the major Omicron BA.2 outbreak in spring 2022 in Shanghai. | Infect Dis Model | 2024 | https://conductscience.org/library/papers/38463154 | PubMed |
| 14 | 32224151 | Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. | Ann Oncol | 2020 | https://conductscience.org/library/papers/32224151 | PubMed |
| 15 | 29718841 | Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: A retrospective study. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/29718841 | PubMed |
| 16 | 35507598 | Characterizing cancer and COVID-19 outcomes using electronic health records. | PLoS One | 2022 | https://conductscience.org/library/papers/35507598 | PubMed |
| 17 | 33275517 | Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. | Am J Physiol Heart Circ Physiol | 2021 | https://conductscience.org/library/papers/33275517 | PubMed |
| 18 | 28728794 | Myeloid suppressor cells in cancer and autoimmunity. | J Autoimmun | 2017 | https://conductscience.org/library/papers/28728794 | PubMed |
| 19 | 32745693 | Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. | Ann Oncol | 2020 | https://conductscience.org/library/papers/32745693 | PubMed |
| 20 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42015103
GET https://conductscience.org/api/papers/v1/42015103/references?page=2